Study of Nab-Paclitaxel in High Risk Early Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Epirubicin|DRUG: nab-Paclitaxel|DRUG: Cyclophosphamide|DRUG: Docetaxel
Sponsor: German Breast Group
Collaborators: Celgene|Amgen